Glut-1 Expression Correlates with Basal-like Breast Cancer

Brenton, 2005, Molecular classification and molecular forecasting of breast cancer: ready for clinical application?, J Clin Oncol, 23, 7350, 10.1200/JCO.2005.03.3845

Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093

Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA, 100, 8418, 10.1073/pnas.0932692100

Sørlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA, 98, 10869, 10.1073/pnas.191367098

Abd El-Rehim, 2005, High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses, Int J Cancer, 116, 340, 10.1002/ijc.21004

Abd El-Rehim, 2004, Expression of luminal and basal cytokeratins in human breast carcinoma, J Pathol, 203, 661, 10.1002/path.1559

Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220

Linderholm, 2009, Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer, Ann Oncol, 20, 1639, 10.1093/annonc/mdp062

Fulford, 2006, Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast, Histopathology, 49, 22, 10.1111/j.1365-2559.2006.02453.x

Matos, 2005, p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas, Virchows Arch, 447, 688, 10.1007/s00428-005-0010-7

Brown, 1998, The unique physiology of solid tumors: opportunities (and problems) for cancer therapy, Cancer Res, 58, 1408

Hockel, 1996, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res, 56, 4509

Semenza, 2000, Hypoxia, clonal selection, and the role of HIF-1 in tumor progression, Crit Rev Biochem Mol Biol, 35, 71, 10.1080/10409230091169186

Behrooz, 1997, Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation, J Biol Chem, 272, 5555, 10.1074/jbc.272.9.5555

Olson, 1996, Structure, function, and regulation of the mammalian facilitative glucose transporter gene family, Annu Rev Nutr, 16, 235, 10.1146/annurev.nu.16.070196.001315

Godoy, 2006, Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues, J Cell Physiol, 207, 614, 10.1002/jcp.20606

Haber, 1998, GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis, Cancer, 83, 34, 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E

Kawamura, 2001, Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival, Cancer, 92, 634, 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X

Younes, 1997, Over-expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival, Cancer, 80, 1046, 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7

Alò, 2001, Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue, Am J Clin Pathol, 116, 129, 10.1309/5Y2L-CDCK-YB55-KDK6

Grover-McKay, 1998, Role for glucose transporter 1 protein in human breast cancer, Pathol Oncol Res, 4, 115, 10.1007/BF02904704

Younes, 1995, GLUT1 expression in human breast carcinoma: correlation with known prognostic markers, Anticancer Res, 15, 2895

Elston, 1991, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111/j.1365-2559.1991.tb00229.x

Fitzgibbons, 2010, Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays, Arch Pathol Lab Med, 134, 930, 10.5858/134.6.930

Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775

Greene, 2002, American Joint Committee on Cancer, xiv

Camp, 2000, Validation of tissue microarray technology in breast carcinoma, Lab Invest, 80, 1943, 10.1038/labinvest.3780204

Amann, 2009, GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis, Am J Pathol, 174, 1544, 10.2353/ajpath.2009.080596

Younes, 1996, Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers, Cancer Res, 56, 1164

Alkushi, 2004, Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level, Int J Gynecol Pathol, 23, 129, 10.1097/00004347-200404000-00007

Carey, 2006, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 295, 2492, 10.1001/jama.295.21.2492

Spitale, 2009, Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland, Ann Oncol, 20, 628, 10.1093/annonc/mdn675

Isselbacher, 1972, Sugar and amino acid transport by cells in culture-differences between normal and malignant cells, N Engl J Med, 286, 929, 10.1056/NEJM197204272861707

Merrall, 1993, Growth factors, mitogens, oncogenes and the regulation of glucose transport, Cell Signal, 5, 667, 10.1016/0898-6568(93)90028-K

Kang, 2002, Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma, Jpn J Cancer Res, 93, 1123, 10.1111/j.1349-7006.2002.tb01214.x

Schwartzenberg-Bar-Yoseph, 2004, The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846

van der Groep, 2008, High frequency of HIF-1α overexpression in BRCA1 related breast cancer, Breast Cancer Res Treat, 111, 475, 10.1007/s10549-007-9817-z

Chappuis, 2000, Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer, Semin Surg Oncol, 18, 287, 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5

Eisinger, 1996, Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer, Cancer Res, 56, 471

Foulkes, 2004, The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer, Cancer Res, 64, 830, 10.1158/0008-5472.CAN-03-2970

Corkery, 2009, Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer, Ann Oncol, 20, 862, 10.1093/annonc/mdn710

Finn, 2008, Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059, Cancer Res, 69, 242s

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113

Rastogi, 2007, Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines, Cancer Lett, 257, 244, 10.1016/j.canlet.2007.07.021

Briasoulis, 2000, J Clin Oncol, 18, 3535, 10.1200/JCO.2000.18.20.3535

Evans, 2008, Increased chemoresistance and HIF-1 independent link with cell turnover is revealed through COMPARE analysis and metabolic studies, Cancer ChemotherPharmacol, 61, 377